Literature DB >> 26147228

IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome.

Hanitriniaina Rabeony1, Mathilde Pohin1, Philippe Vasseur1,2, Isabelle Petit-Paris1,2, Jean-François Jégou1, Laure Favot1, Eric Frouin1,2, Marie-Astrid Boutet3, Frédéric Blanchard3, Dieudonnée Togbe4, Bernhard Ryffel5, François-Xavier Bernard1,6, Jean-Claude Lecron1,2, Franck Morel1.   

Abstract

The pathogenesis of inflammatory skin diseases such as psoriasis involves the release of numerous proinflammatory cytokines, including members of the IL-1 family. Here we report overexpression of IL-1α, IL-1β, and IL-1 receptor antagonist mRNA, associated to expression of IL-23p19, IL-17A, and IL-22 in skin cells, upon topical application of the TLR7 agonist imiquimod (IMQ) in C57BL/6J mice. IMQ-induced skin inflammation was partially reduced in mice deficient for both IL-1α/IL-1β or for IL-1 receptor type 1 (IL-1R1), but not in IL-1α- or IL-1β-deficient mice, demonstrating the redundant activity of IL-1α and IL-1β for skin inflammation. NLRP3 or apoptosis-associated Speck-like protein containing a Caspase recruitment domain-deficient mice had no significant reduction of skin inflammation in response to IMQ treatment, mainly due to the redundancy of IL-1α. However, IMQ-induced skin inflammation was abolished in the absence of MyD88, the adaptor protein shared by IL-1R and TLR signaling pathways. These results are consistent with the TLR7 dependence of IMQ-induced skin inflammation. Thus, IL-1R1 contributes to the IMQ-induced skin inflammation, and disruption of MyD88 signaling completely abrogates this response.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  IL-1R; Imiquimod; MyD88; NLRP3 inflammasome; Skin inflammation

Mesh:

Substances:

Year:  2015        PMID: 26147228     DOI: 10.1002/eji.201445215

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice.

Authors:  Nicholas J Geraghty; Kylie J Mansfield; Stephen J Fuller; Debbie Watson; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2017-06-08       Impact factor: 3.765

2.  Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis.

Authors:  Julio A Diaz-Perez; Meaghan E Killeen; Yin Yang; Cara D Carey; Louis D Falo; Alicia R Mathers
Journal:  J Invest Dermatol       Date:  2018-06-02       Impact factor: 8.551

3.  Praziquantel Targets M1 Macrophages and Ameliorates Splenomegaly in Chronic Schistosomiasis.

Authors:  Delong Kong; Chunlei Zhou; Hongfei Guo; Wei Wang; Jingfan Qiu; Xinjian Liu; Jinfeng Liu; Lijuan Wang; Yong Wang
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

4.  Epithelial TRAF6 drives IL-17-mediated psoriatic inflammation.

Authors:  Reiko Matsumoto; Teruki Dainichi; Soken Tsuchiya; Takashi Nomura; Akihiko Kitoh; Matthew S Hayden; Ken J Ishii; Mayuri Tanaka; Tetsuya Honda; Gyohei Egawa; Atsushi Otsuka; Saeko Nakajima; Kenji Sakurai; Yuri Nakano; Takashi Kobayashi; Yukihiko Sugimoto; Kenji Kabashima
Journal:  JCI Insight       Date:  2018-08-09

5.  Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.

Authors:  M-A Boutet; G Bart; M Penhoat; J Amiaud; B Brulin; C Charrier; F Morel; J-C Lecron; M Rolli-Derkinderen; A Bourreille; S Vigne; C Gabay; G Palmer; B Le Goff; F Blanchard
Journal:  Clin Exp Immunol       Date:  2016-02-22       Impact factor: 4.330

6.  Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis.

Authors:  Elodie Couderc; Franck Morel; Pierre Levillain; Amandine Buffière-Morgado; Magalie Camus; Camille Paquier; Charles Bodet; Jean-François Jégou; Mathilde Pohin; Laure Favot; Martine Garcia; Vincent Huguier; Jiad Mcheik; Corinne Lacombe; Hans Yssel; Gérard Guillet; François-Xavier Bernard; Jean-Claude Lecron
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

Review 7.  The Role of NLRP1, NLRP3, and AIM2 Inflammasomes in Psoriasis: Review.

Authors:  Magdalena Ciążyńska; Irmina Olejniczak-Staruch; Dorota Sobolewska-Sztychny; Joanna Narbutt; Małgorzata Skibińska; Aleksandra Lesiak
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

Review 8.  NLRP3 inflammasome and its inhibitors: a review.

Authors:  Bo-Zong Shao; Zhe-Qi Xu; Bin-Ze Han; Ding-Feng Su; Chong Liu
Journal:  Front Pharmacol       Date:  2015-11-05       Impact factor: 5.810

9.  Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33.

Authors:  Sara Khaleghparast Athari; Elodie Poirier; Jérôme Biton; Luca Semerano; Roxane Hervé; Aurélie Raffaillac; Delphine Lemeiter; André Herbelin; Jean-Philippe Girard; Frédéric Caux; Marie-Christophe Boissier; Natacha Bessis
Journal:  Arthritis Res Ther       Date:  2016-06-18       Impact factor: 5.156

10.  A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress.

Authors:  Yan-Feng Zhang; Chen-Chen Sun; Jia-Xi Duan; Hui-Hui Yang; Chen-Yu Zhang; Jian-Bing Xiong; Wen-Jing Zhong; Cheng Zu; Xin-Xin Guan; Hui-Ling Jiang; Bruce D Hammock; Sung Hee Hwang; Yong Zhou; Cha-Xiang Guan
Journal:  Biomed Pharmacother       Date:  2020-02-27       Impact factor: 6.529

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.